AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04387591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
Study NCT04874649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon-blowing breathing
Description: Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
Study NCT03128372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desaturation
Description: The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study NCT04296344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy Treatments
Description: 10 consecutive weekly group acupuncture therapy treatments
Study NCT04296344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Sessions
Description: 8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
Study NCT03272009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Capsules administered orally. Number of morning and evening capsules depending on treatment arm
Study NCT04874649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained maximal inspiration breathing
Description: Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
Study NCT03272009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
Study NCT03272009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets administered orally
Study NCT03272009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Ready-to-Use pre-filled syringes for subcutaneous injection
Study NCT03272009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peg-interferon alfa-2a
Description: Ready-to-Use pre-filled syringes for subcutaneous injection
Study NCT00945685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endymion Imagine™ System for Skin Tightening
Description: Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);
Study NCT03196206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral Suspension
Study NCT00782756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiotherapy (RT) in combination with temozolomide and bevacizumab
Description: Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly.
Study NCT03515265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber reinforced resin composite restoration
Description: a type of resin composite with improved strength due to the fiber's action
Study NCT03515265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microhybrid resin composite restoration
Description: a type of conventional resin composite
Study NCT03979495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mFOCUS
Description: To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
Study NCT03421249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Muscle strengthening exercises of the hip and knee muscles
Study NCT03421249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic field therapy
Description: Electromagnetic field therapy with Magnetron®
Study NCT00871468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior plate
Description: Open reduction internal fixation (ORIF) clavicle with superior plate
Study NCT00871468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior-inferior plate
Description: ORIF clavicle with anterior inferior plate
Study NCT03421249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electromagnetic field therapy
Description: Electromagnetic field therapy with Magnetron®
Study NCT04378894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
Study NCT04378894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
Study NCT02470169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merional
Description: On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
Study NCT02470169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
Study NCT02470169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriomon
Description: Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
Study NCT02470169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shepherd catheter
Study NCT02470169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovulation detection
Description: Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
Study NCT01085513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam SB2
Description: The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
Study NCT04124952 — intervention group
Intervention type: DEVICE
Intervention: Panoptix
Description: Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
Study NCT03603340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT03603340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT02286336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brachial plexus block
Description: brachial plexus block with ropivacaine 40ml
Study NCT02286336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: brachial plexus block with ropivacaine 40ml
Study NCT02082652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
Study NCT03542305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib single oral dose
Study NCT03727685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Our Care Wishes
Description: A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
Study NCT03542305 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorlatinib
Description: Lorlatinib single oral dose
Study NCT02741505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: Participants will be asked to wear an actigraph
Study NCT02565966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Description: For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
Study NCT02195856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: 140mL concentrated Beetroot juice or placebo juice
Study NCT02195856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00649857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Tablets 10 mg
Description: 10mg, single dose fed
Study NCT00649857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® 10 mg
Description: 10mg, single dose fed
Study NCT02024217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: S1，oxaliplatin，radiation
Description: Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
Study NCT01793779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold water immersion
Study NCT04543565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet
Description: Once daily
Study NCT01793779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)
Study NCT01793779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01793779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05302115 — intervention group
Intervention type: DEVICE
Intervention: S-ICD
Description: Implantation of an S-ICD
Study NCT02322372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral blockade
Description: Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
Study NCT04543565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate
Description: Once daily
Study NCT01108224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Description: Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
Study NCT01702402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and Behavior Change intervention
Description: Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM.
Study NCT01702402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Group
Description: A comparison area received standard government health services.
Study NCT00161720 — intervention group
Intervention type: DRUG
Intervention: Protein C Concentrate (Human) Vapor Heated
Description: Protein C Concentrate (Human) Vapor Heated
Study NCT03769857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM® + BIOCURC®
Description: Dietary supplement combination for the support of joint health.
Study NCT03769857 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02972294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
Study NCT02972294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be use.
Study NCT02972294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos iron isomaltoside 1000
Description: placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
Study NCT02972294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos tranexamic acid
Description: placebo of tranexamic acid correspond to a saline solution.
Study NCT01011764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKILLS vs ENGAGE
Description: The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
Study NCT01011764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SKILLS vs ENGAGE
Description: The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
Study NCT00741910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: semapimod IV 60 mg x 3 days q 6 - 10 weeks
Study NCT03082768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-968
Description: Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
Study NCT01444144 — intervention group
Intervention type: OTHER
Intervention: Fracture union
Description: Retrospective records review post-operatively until fracture resolved.
Study NCT00671515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
Study NCT03907293 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise-based cardiac rehabilitation
Description: Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
Study NCT02324413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Comparison between placebo and 2 different concentrations of clonidine
Study NCT02324413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02340936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 5 mg)
Description: 3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study NCT02340936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-ESHAP (lenalidomide 10 mg)
Description: 3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
Study NCT03447990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MYK-491
Description: Single Ascending Dose and Multiple Ascending Dose of MYK-491
Study NCT03447990 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Single Ascending Dose and Multiple Ascending Dose of placebo
Study NCT03287505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
Study NCT04356274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory System Dynamics (PSD)
Description: Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study NCT04356274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (AF)
Description: Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
Study NCT02322372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal anesthesia
Description: Spinal anesthesia with heavy bupivacaine
Study NCT02767999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg of fluoxetine capsule per day from D0 to D90
Study NCT02767999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose placebo per day from D0 to D90
Study NCT02767999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional resting state MRI
Study NCT02767999 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: fMRI
Description: functional resting state MRI